ArticleAdvanced biomedical research2025
Comparison of Various Dosages of Escitalopram on Anxiety-like Behavior and Body Weight in Male Rats under Severe Chronic Stress.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stress and escitalopram impact mood and various physiological systems. The present study aimed to compare the protective effects of different dosages of escitalopram on anxiety-like behavior and body weight in male rats subjected to severe chronic stress. Materials and Methods: Rats were randomly divided into groups: control, stress, sham, escitalopram (10 mg/kg and 20 mg/kg), and stress-escitalopram (10 mg/kg and 20 mg/kg). Restraint stress was induced 6h/day/14 days, and escitalopram was administered concurrently. The number of open arm entries (OAE%) and the total time spent in the open arms (OAT%) were assessed using the elevated plus maze test. Results: There were significant reductions in latency, OAT%, and OAE% within the stressed group. OAT% showed a notable increase in the Stress-Escitalopram10 and Stress-Escitalopram 20 groups when compared to the stressed group. Both OAT% and OAE% significantly decreased in the Stress-Escitalopram20 compared to the Stress-Escitalopram10. There were significant reductions in body weight differences across all experimental groups. The body weight in the Stress-Escitalopram20 was significantly lower than that of the group receiving only escitalopram at a dosage of 20 mg/kg. Conclusion: Escitalopram did not induce significant changes in anxiety-like behavior under stress-free conditions. The simultaneous administration of escitalopram, particularly at a dosage of 10 mg/kg, exhibited a protective effect in reversing of anxiety-like behavior under stressed conditions. Both doses of escitalopram resulted in a reduction of body weight in both stress and stress-free conditions, highlighting the dual behavioral and physiological effects of escitalopram. These findings offer novel insights into the dose-specific effects and potential side effects of escitalopram, thereby informing its clinical application for stress-related disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.